PharmaShots | Incisive News in 3 Shots

Subscribe Now

First New Medication

Bristol-Myers's Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs

Bristol-Myers's Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs

August 17, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us